Page 264 - Binder2

infrastructure—embedded into how we feed, heal, and
stabilize societies.

A New Therapeutic Architecture

Edible biologics represent more than a cost advantage or
delivery shift.
They introduce a new architecture for medicine:

• Where drugs are grown regionally, not centralized
• Where immune tolerance is built in, not managed
downstream
• Where treatment is ambient, not cold-chained
• Where biologics are part of daily life, not episodic
intervention
• Where the most advanced science reaches the
places with the least infrastructure

This is not a tweak to the system.
It’s a parallel system—one that can reach where the old
one cannot.

The Opportunity Ahead

Every breakthrough in biotech—recombinant proteins,
monoclonal antibodies, gene therapy—faced skepticism at
first.
Each required new frameworks, new standards, new mental
models.
Edible biologics are no different.

But for those willing to lead, the opportunity is massive:

262